201. Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery.
- Author
-
Tanaka, Takayuki, Takahashi, Kazutoshi, Yamane, Mayu, Tomida, Shota, Nakamura, Saori, Oshima, Koichi, Niwa, Akira, Nishikomori, Ryuta, Kambe, Naotomo, Hara, Hideki, Mitsuyama, Masao, Morone, Nobuhiro, Heuser, John E., Yamamoto, Takuya, Watanabe, Akira, Otsubo, Aiko Sato, Ogawa, Seishi, Asaka, Isao, Heike, Toshio, and Yamanaka, Shinya
- Subjects
- *
INFLAMMATION , *INDUCED pluripotent stem cells , *PHARMACEUTICAL research , *GENETIC mutation , *CELL differentiation , *DRUG use testing - Abstract
Chronic infantile neurologic cutaneous and articular (CINCA) syndrome is an IL-1-driven autoinflammatory disorder caused mainly by NLRP3 mutations. The pathogenesis of CINCA syndrome pa-tients who carry NLRP3 mutations as somatic mosaicism has not been pre-cisely described because of the difficulty in separating Individual cells based on the presence or absence of the mutation. Here we report the generation of NLRP3mutant and nonmutant-induced pluripo-tent stem cell (iPSC) lines from 2 CINCA syndrome patients with somatic mosa-icism, and describe their differentiation into macrophages (IPS-MPs). We found that mutant cells are predominantly re-sponsible for the pathogenesis in these mosaic patients because only mutant IPS-MPs showed the disease relevant pheno-type of abnormal IL-1ß secretion. We also confirmed that the existing anti- inflammatory compounds inhibited the abnormal IL-1 p secretion, indicating that mutant iPS-MPs are applicable for drug screening for CINCA syndrome and other NLRP3-related Inflammatory conditions. Our results illustrate that patient-derived iPSCs are useful for dissecting somatic mosaicism and that A/L/?P3-mutant iPSCs can provide a valuable platform for drug discovery for multiple NLRP3-related dis-orders. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF